Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Adial Pharmaceuticals Inc (ADIL)

Adial Pharmaceuticals Inc (ADIL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,784
  • Shares Outstanding, K 4,233
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,120 K
  • 60-Month Beta 1.31
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.76
Trade ADIL with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.39
  • Number of Estimates 1
  • High Estimate -0.39
  • Low Estimate -0.39
  • Prior Year -1.33
  • Growth Rate Est. (year over year) +70.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0000 +13.00%
on 07/05/24
1.3950 -19.00%
on 06/14/24
-0.1500 (-11.72%)
since 06/12/24
3-Month
1.0000 +13.00%
on 07/05/24
3.1000 -63.55%
on 04/15/24
-1.2000 (-51.50%)
since 04/12/24
52-Week
0.7650 +47.71%
on 02/23/24
8.8750 -87.27%
on 07/31/23
-7.0200 (-86.13%)
since 07/12/23

Most Recent Stories

More News
Adial Pharmaceuticals Announces Topline Results For Onward™ Phase 3 Trial for AD04 in Patients with Alcohol Use Disorder

AD04 achieved statistically significant mean reduction in heavy drinking days among pre-specified group of heavy drinkers, compared to placebo, with an...

ADIL : 1.1300 (-0.88%)
ADILW : 0.0009 (-57.14%)
Adial Pharmaceuticals to Announce Topline Results of ONWARD™ Phase 3 Trial for AD04 in Patients With Alcohol Use Disorder

Company to host conference call on Wednesday, July 20, 2022, at 1 PM ET...

ADIL : 1.1300 (-0.88%)
ADILW : 0.0009 (-57.14%)
Twin Vee PowerCats Co.'s Board of Directors Appoints Kevin Schuyler as Newest Director

FORT PIERCE, FL / ACCESSWIRE / July 7, 2022 / Twin Vee PowerCats Co. (Nasdaq:VEEE) ("Twin Vee" or the "Company"), a designer, manufacturer, distributor, and marketer of power sport catamaran boats, today...

VEEE : 0.5811 (+3.56%)
ADIL : 1.1300 (-0.88%)
Adial Pharmaceuticals Provides Letter to Shareholders From CEO William Stilley

CHARLOTTESVILLE, Va., June 28, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today issued the...

ADIL : 1.1300 (-0.88%)
ADILW : 0.0009 (-57.14%)
Adial Pharmaceuticals Announces Database Lock for the ONWARD™ Phase 3 Clinical Trial

Expects Release of Top-Line Data in July...

ADIL : 1.1300 (-0.88%)
ADILW : 0.0009 (-57.14%)
Adial Pharmaceuticals Announces Database Lock for the ONWARD™ Phase 3 Clinical Trial

Expects Release of Top-Line Data in July...

ADIL : 1.1300 (-0.88%)
ADILW : 0.0009 (-57.14%)
Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence

New patent covers the use of the full genetic panel measuring all five genetic biomarkers...

ADIL : 1.1300 (-0.88%)
ADILW : 0.0009 (-57.14%)
Adial Pharmaceuticals Announces Research Collaboration with the Medical College of Wisconsin to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Diabetes and NASH

CHARLOTTESVILLE, Va., May 19, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that...

ADIL : 1.1300 (-0.88%)
ADILW : 0.0009 (-57.14%)
Adial Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

Nears completion of ONWARD™ Phase 3 pivotal trial of AD04 for the treatment of Alcohol Use Disorder; on track to report Phase 3 results in the current...

ADIL : 1.1300 (-0.88%)
ADILW : 0.0009 (-57.14%)
Adial Pharmaceuticals Announces Research Collaboration with UC San Diego to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Inflammatory Diseases & Disorders

CHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that...

ADIL : 1.1300 (-0.88%)
ADILW : 0.0009 (-57.14%)

Business Summary

Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. The company's lead product consists of AD04 which is in clinical stage. Adial Pharmaceuticals Inc. is based in CHARLOTTESVILLE.

See More

Key Turning Points

3rd Resistance Point 1.2167
2nd Resistance Point 1.1833
1st Resistance Point 1.1567
Last Price 1.1300
1st Support Level 1.0967
2nd Support Level 1.0633
3rd Support Level 1.0367

See More

52-Week High 8.8750
Fibonacci 61.8% 5.7770
Fibonacci 50% 4.8200
Fibonacci 38.2% 3.8630
Last Price 1.1300
52-Week Low 0.7650

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar